webleads-tracker

Pharma Compliance Info Open Payments: Research Payments Distorted by Including Value of the Medicines and Devices US Sunshine Act

Open Payments: Research Payments Distorted by Including Value of the Medicines and Devices

October 20, 2015. By Thomas Sullivan.Pharma Compliance Info Open Payments: Research Payments Distorted by Including Value of the Medicines and Devices US Sunshine Act
The Open Payments program, an element of the Affordable Care Act (the “Sunshine Act”), has required the healthcare industry to adhere to a complex transparency program since its implementation in 2014. The Act is an attempt to track payments and transfers of value between life sciences manufacturers and healthcare professionals, and requires any payments and transfers of value to be reported publicly on the Open Payments website. Many have been concerned that such a requirement has the potential to do more harm than good, especially since the reliability of the data has been called into question.
According to the Wall Street Journal, a group from Johns Hopkins University argues that the required reported information creates a “distorted” image of the money that doctors might receive, because for the research template it does not break out a specific value to medicines that pharmaceutical companies provide for clinical trials. “Donated drugs are intended for use by patients and do not provide direct monetary value to physician-investigators. The Open Payment rules for research cloud this critical distinction. One may presume that the public may have difficulty distinguishing between donated drugs for research and transfers of financial value to physicians.”
To read the article by Thomas Sullivan

Check Also

Pharma Compliance Info The Patient Advocacy Groups that Accept the Most Big Pharma Money US Sunshine Act

The Patient Advocacy Groups that Accept the Most Big Pharma Money

Eight out of ten patient advocacy groups accept money from drug and medical device companies. …

X